LNAI · Lunai Bioworks Inc.

Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute . Company CEO David Weinstein shared how the company is using its proprietary AI platform to scale therapeutic discovery and strengthen biodefense preparedness. "We are deploying AI to accelerate discovery in CNS disease and biodefense," said David Weinstein, Chief Executive Officer of Lunai Bioworks. "Our platform is built to scale precision biology, reduce development risk, and advance high-impact therapeutic programs more efficiently." During the national segment, Weinstein discussed how Lunai integrates multimodal biological datasets, advanced machine learning, and in vivo validation systems to rapidly identify novel targets, optimize drug candidates, and compress development timelines across complex neurological disorders and emerging chemical and biological threat countermeasures. The CNBC appearance underscores growing investor attention on scalable AI platforms

Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial. Negotiations are moving forward with several pharmaceutical and drug discovery companies. Partnerships and collaborations are imminent. Why? -because Lunai Bioworks operates a closed loop AI system that is truly disruptive (and complementary) to current discovery platforms and that turns complex biology into real-world action in several ways with less cash burn and new revenue streams. Our Augusta platform starts with real biological signals from patients — genetic, molecular, and clinical data — and uses artificial intelligence to reverse-engineer diseases into biologically defined subgroups. Instead of asking, "What drug hits this target?" Lunai asks, "What biology is actually driving this subgroup of patients?" Then comes the part most AI companies can't do. Lunai rapidly tests its predictions in living systems using high-throughput in vivo models. That means its drug ideas aren't

, an AI-powered drug discovery and biodefense company, today announced the launch of a new oncology collaboration with a clinical-stage partner to analyze data from a randomized Phase 2 metastatic colorectal cancer trial . The objective is to define biologically meaningful patient subgroups that may benefit most from the investigational therapy. Under the pilot agreement, Lunai will deploy its proprietary Augusta AI platform to evaluate de-identified patient-level clinical, imaging, and longitudinal outcomes data, with a focus on overall survival and disease progression endpoints. By integrating traditional clinical variables with AI-derived imaging features and temporal response patterns , Lunai aims to generate data-driven enrichment strategies designed aid in the FDA trial design , including optimized inclusion criteria, endpoint strategy, and its statistical powering. "This collaboration reflects how AI can unlock hidden value in existing oncology datasets," said David Weinstein,

Transformer-based biosecurity layer embeds directly into foundation models, using Lunai's proprietary toxicology and in-vivo datasets to detect and prevent creation of previously unknown threat agents in real time . As global attention intensifies around the dual-use risks of advanced artificial intelligence in chemistry and biology, Lunai Bioworks (NASDAQ: LNAI) today announced the deployment of Sentinel™, a transformer-based AI safeguard designed to be embedded directly within large language and scientific foundation models to prevent the generation of novel chemical agents. Built on Lunai's expansive molecular AI platform and strengthened by proprietary toxicology and in-vivo phenotypic datasets, Sentinel operates as a real-time biosecurity layer, screening molecular outputs before they are produced and stopping potentially hazardous designs at the source. The launch positions Lunai at the forefront of AI safety infrastructure as governments, regulators, and

Lunai Bioworks (NASDAQ: LNAI ), an AI-powered drug discovery and biodefense company, today announced it has completed a key commercial milestone under its NIH STTR-supported initiative, generating high-resolution, multidimensional behavioral signatures of ethanol exposure and alcohol withdrawal. Using high-throughput vertebrate screening, the company identified distinct, reproducible neurobehavioral phenotypes that are only partially addressed by currently approved therapies, highlighting previously underexplored biological mechanisms with strong translational potential. Based on these results, the company has initiated a new commercial drug discovery program targeting Alcohol Use Disorder (AUD), a condition affecting approximately 30 million individuals in the U.S. alone, with over 95% receiving no effective pharmacologic treatment. Lunai's AUD program is designed to advance differentiated, mechanism-informed therapeutic candidates toward clinical translation, while